Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Int J Med Mushrooms ; 23(2): 1-11, 2021.
Article in English | MEDLINE | ID: covidwho-1105918

ABSTRACT

This review provides results obtained by scientists from different countries on the antiviral activity of medicinal mushrooms against influenza viruses that can cause pandemics. Currently, the search for antiviral compounds is relevant in connection with the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Medicinal mushrooms contain biologically active compounds (polysaccharides, proteins, terpenes, melanins, etc.) that exhibit an antiviral effect. The authors present the work carried out at the State Research Center of Virology and Biotechnology Vector in Russia, whose mission is to protect the population from biological threats. The research center possesses a collection of numerous pathogenic viruses, which allowed screening of water extracts, polysaccharides, and melanins from fruit bodies and fungal cultures. The results of investigations on different subtypes of influenza virus are presented, and special attention is paid to Inonotus obliquus (chaga mushroom). Compounds produced from this mushroom are characterized by the widest range of antiviral activity. Comparative data are presented on the antiviral activity of melanin from natural I. obliquus and submerged biomass of an effective strain isolated in culture against the pandemic strain of influenza virus A/California/07/09 (H1N1 pdm09).


Subject(s)
Agaricales/chemistry , Antiviral Agents/pharmacology , Biological Factors/pharmacology , Orthomyxoviridae/drug effects , Animals , Antiviral Agents/isolation & purification , Biological Factors/isolation & purification , Humans , Inonotus/chemistry , Melanins/isolation & purification , Melanins/pharmacology , Orthomyxoviridae/classification , Pandemics , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/virology
2.
Phytother Res ; 35(6): 3013-3031, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-996303

ABSTRACT

In times of health crisis, including the current COVID-19 pandemic, the potential benefit of botanical drugs and supplements emerges as a focus of attention, although controversial efficacy claims are rightly a concern. Phytotherapy has an established role in everyday self-care and health care, but, since botanical preparations contain many chemical constituents rather than single compounds, challenges arise in demonstrating efficacy and safety. However, there is ample traditional, empirical, and clinical evidence that botanicals can offer some protection and alleviation of disease symptoms as well as promoting general well-being. Newly emerging viral infections, specifically COVID-19, represent a unique challenge in their novelty and absence of established antiviral treatment or immunization. We discuss here the roles and limitations of phytotherapy in helping to prevent and address viral infections, especially regarding their effects on immune response. Botanicals with a documented immunomodulatory, immunostimulatory, and antiinflammatory effects include adaptogens, Boswellia spp., Curcuma longa, Echinacea spp., Glycyrrhiza spp., medicinal fungi, Pelargonium sidoides, salicylate-yielding herbs, and Sambucus spp. We further provide a clinical perspective on applications and safety of these herbs in prevention, onset, progression, and convalescence from respiratory viral infections.


Subject(s)
COVID-19 Drug Treatment , Plant Preparations/pharmacology , Plants, Medicinal/chemistry , Dietary Supplements , Humans , Immunity/drug effects , Phytotherapy/methods , SARS-CoV-2/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL